Biosynex extends tender offer for the shares of chembio diagnostics, inc.

Strasbourg, france, march 15, 2023 (globe newswire) -- biosynex sa (“biosynex”) (epa: albio), a french market leader specializing in the design and distribution of rapid tests, today announced that project merci merger sub, inc. (“purchaser”), a nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “shares”) of chembio diagnostics, inc. (nasdaq: cemi) (“chembio”) at a price of $0.45 per share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., new york city time on march 28, 2023, unless further extended. the tender offer was previously scheduled to expire at one minute after 11:59 p.m., new york city time, on march 14, 2023. all other terms and conditions of the tender offer remain unchanged.
CEMI Ratings Summary
CEMI Quant Ranking